1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €276.92 (+32.50%). The median is €284.40 (+36.08%).
| Buy |
Â
24 |
| Hold |
Â
2 |
| Sell |
Â
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 344.9M | 118.23% |
| Gross profit | 312.61M | 146.93% |
| Net profit | 210.4M | 641.49% |
| EBITDA | 68.08M | 2,835.57% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €13.42B |
Number of shares | 62.11M |
52-week high/low | €246.15 - €162.31 |
| Dividends | No |
Beta | 0.38 |
P/E ratio | 17.86 |
PEG ratio | 0.03 |
P/B ratio | 9.68 |
P/S ratio | 12.73 |
Company profile
| Name | Ascendis Pharma ADR |
| CEO | Jan Moller Mikkelsen |
| Employees | 1,189 |
